Published in Nat Rev Cancer on August 01, 2006
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
The H19 non-coding RNA is essential for human tumor growth. PLoS One (2007) 3.75
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med (2008) 3.00
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 2.93
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis (2008) 2.21
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun (2011) 1.84
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov (2014) 1.58
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med (2016) 1.38
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res (2010) 1.38
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep (2008) 1.36
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer (2010) 1.31
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol (2010) 1.30
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.24
Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res (2007) 1.22
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A (2011) 1.20
Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget (2015) 1.16
Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget (2015) 1.13
Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res (2009) 1.11
Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia (2009) 1.10
E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res (2010) 1.10
Expression of the c-Met Proteins in Malignant Skin Cancers. Ann Dermatol (2011) 1.09
miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev (2015) 1.08
Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med (2012) 1.08
The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res (2010) 1.08
CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem (2011) 1.07
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem (2010) 1.06
Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer (2008) 1.06
Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol (2009) 1.06
Metastasis and stem cell pathways. Cancer Metastasis Rev (2007) 1.04
Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med (2010) 1.03
c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol (2009) 1.01
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget (2016) 1.00
HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers. J Cell Sci (2010) 1.00
Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2012) 1.00
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist (2013) 0.98
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs (2012) 0.98
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One (2013) 0.96
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. Onco Targets Ther (2014) 0.96
Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS One (2011) 0.95
Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A (2007) 0.95
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis (2011) 0.95
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95
Degenerate wave and capacitive coupling increase human MSC invasion and proliferation while reducing cytotoxicity in an in vitro wound healing model. PLoS One (2011) 0.93
Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol (2015) 0.93
On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210. Front Pharmacol (2012) 0.93
Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver (2015) 0.92
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer (2014) 0.92
c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF. J Hepatol (2011) 0.91
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget (2014) 0.91
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci (2014) 0.91
HIF-1α Overexpression Induces Angiogenesis in Mesenchymal Stem Cells. Biores Open Access (2012) 0.90
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl) (2013) 0.90
Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin Cancer Res (2013) 0.90
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med (2014) 0.90
Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget (2016) 0.89
Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest (2014) 0.89
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron (2015) 0.89
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene (2015) 0.88
A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells (2012) 0.88
Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med (2011) 0.87
Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. J Biol Chem (2009) 0.87
A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer (2012) 0.87
c-Met-dependent multipotent labyrinth trophoblast progenitors establish placental exchange interface. Dev Cell (2013) 0.86
Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One (2012) 0.86
Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene (2010) 0.86
Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer (2011) 0.85
Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. Virchows Arch (2012) 0.85
Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer (2015) 0.84
Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis. Oncogene (2015) 0.84
Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther (2014) 0.84
MET and Small-Cell Lung Cancer. Cancers (Basel) (2014) 0.83
c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol (2014) 0.83
Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One (2015) 0.83
Disturbance of Ca2+ homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells. J Biol Chem (2012) 0.82
The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem (2012) 0.82
Hepatocyte growth factor increases the invasive potential of PC-3 human prostate cancer cells via an ERK/MAPK and Zeb-1 signaling pathway. Oncol Lett (2015) 0.82
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med (2016) 0.82
Can oncology recapitulate paleontology? Lessons from species extinctions. Nat Rev Clin Oncol (2015) 0.82
Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. Oncogenesis (2013) 0.82
Linking MLL and the HGF-MET signaling pathway in liver cancer. J Clin Invest (2013) 0.81
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics. Cell Cycle (2015) 0.81
Rationally designed treatment for metastatic colorectal cancer: current drug development strategies. World J Gastroenterol (2014) 0.81
Transglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-κB Pathway. Biomol Ther (Seoul) (2012) 0.81
Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis. Acta Neuropathol Commun (2014) 0.80
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model. PLoS One (2013) 0.80
Engineered variants of InlB with an additional leucine-rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complex. Protein Sci (2012) 0.80
Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population. Chin J Cancer Res (2012) 0.80
Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol (2016) 0.79
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis (2012) 0.79
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth. Front Pharmacol (2012) 0.79
Activated Met signalling in the developing mouse heart leads to cardiac disease. PLoS One (2011) 0.79
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol (2016) 0.79
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget (2016) 0.79
HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer. Genes Dev (2016) 0.79
Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacol Sin (2013) 0.78
A protocol for genetic induction and visualization of benign and invasive tumors in cephalic complexes of Drosophila melanogaster. J Vis Exp (2013) 0.78
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99
The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol (2002) 2.74
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 2.61
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47
The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev (2008) 2.41
The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 2.02
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
The Met pathway: master switch and drug target in cancer progression. FASEB J (2006) 1.74
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res (2011) 1.52
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res (2012) 1.51
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
To move or not to move? Semaphorin signalling in cell migration. EMBO Rep (2004) 1.42
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest (2010) 1.41
Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep (2004) 1.39
The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature (2005) 1.37
Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med (2003) 1.37
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol (2006) 1.37
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res (2003) 1.34
Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res (2011) 1.32
p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. J Cell Sci (2005) 1.31
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res (2002) 1.26
Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res (2004) 1.26
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest (2004) 1.25
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res (2005) 1.20
Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem (2004) 1.16
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
Functional regulation of semaphorin receptors by proprotein convertases. J Biol Chem (2003) 1.10
Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol (2005) 1.10
MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res (2006) 1.09
Cancer: the matrix is now in control. Nat Med (2005) 1.09
Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs (2010) 1.09
The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res (2010) 1.08
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res (2011) 1.07
Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res (2011) 1.06
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem (2010) 1.06
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem (2008) 1.06
Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal (2009) 1.02
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res (2014) 1.02
The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J Biol Chem (2010) 1.01
Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J Clin Invest (2009) 1.00
The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med (2008) 0.99
Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res (2004) 0.98
Invasive growth: a genetic program. Int J Dev Biol (2004) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Mol Biol Cell (2008) 0.97
"Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res (2008) 0.97
A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem (2010) 0.95
Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res (2010) 0.93
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer (2011) 0.93
Genetic link between cancer and thrombosis. J Clin Oncol (2009) 0.93
Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal (2009) 0.91
The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res (2013) 0.90
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. PLoS One (2008) 0.90
p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer (2006) 0.89
An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nat Biotechnol (2002) 0.88
Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci (2003) 0.87
Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. J Biol Chem (2003) 0.86
A functional role for hemostasis in early cancer development. Cancer Res (2005) 0.85
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther (2013) 0.84
Invasive growth: a two-way street for semaphorin signalling. Nat Cell Biol (2004) 0.80
Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology (2008) 0.80
Feline STK gene expression in mammary carcinomas. Oncogene (2002) 0.79
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol (2014) 0.78
A differentiation switch for genetically modified hepatocytes. FASEB J (2001) 0.78
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. J Mol Med (Berl) (2013) 0.76